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Introduction 
Prevention and treatment of central nervous system (CNS) metastases remain a major prob- 
lem in the treatment of small cell lung cancer (SCLC). CNS metastases are normally cate- 
gorized into parenchymal (brain) metastases, leptomeningeal carcinomatosis and spinal cord 
compression. The incidence rises with the length of survival [l-3]. The methodological difficul- 
ties in establishing the true dimensions of the problem and in evaluating treatment results have 
been addressed recently elsewhere [4,5]. The present report summarizes information obtained 
since the last IASLC workshop consensus report [6]. It includes points of interest for future 
work along with guidelines, in so far as current knowledge permits recommendations to be 
made. In-depth analysis of the role of elective cranial irradiation (PO, chemo- and radiother- 
apy of CNS metastases and sequelae of these treatments has been prepared in conjunction with 
the present workshop and can be found elsewhere in this issue [7-91. 
Elective cranial irradiation (PCI) 
Since the 1981 consensus report no additional trials on the value of PC1 in patients obtaining 
a complete remission have been published. Retrospective evaluations of patients receiving and 
not receiving PC1 have been published and reviewed elsewhere [5,7]. 
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The available information suggests the following. 
(1) Approximately 10% of patients who achieve a complete response and do not receive PC1 
develop brain metastases as the sole site of recurrent disease. 
(2) PC1 prolongs the period before occult brain metastases become symptomatic, but may not 
prevent their eventual occurrence. 
(3) Patients receiving PCI may be at greater risk of developing late neuro-psychological com- 
plications. 
Currently the value of PC1 in patients who obtain a complete response is under investigation 
in two ongoing trials, but additional randomized trials are needed. 
Apart from looking at whether or not PC1 should be given, information on the proper timing 
and optimal dosage is important. In such studies, information on the type of chemotherapy ad- 
ministered, and whether it is given concurrently with the PC1 should be included. In addition, 
the use of corticosteroids may be of importance. Patients should be evaluated before PC1 and at 
preset intervals thereafter. The evaluation should include contrast enhanced brain CT-scans and 
some semi-quantitative determination of the cerebral function with an established methodology. 
On the basis of current knowledge, the use of PC1 in patients in complete remission is con- 
sidered optional in the non-investigational setting. For patients who do not obtain a complete re- 
sponse there is little evidence to support the use of PCI. 
Treatment of CNS metastases 
Most questions concerning the treatment of CNS metastases raised in the 1981 consensus re- 
port unfortunately remain unanswered [6]. Additional points have emerged following a number 
of recent reports on the use of chemotherapy in the treatment of brain metastases [9]. The major 
problems in evaluating current treatment possibilities, such as e.g. definition of endpoints, selec- 
tion of patients, and impact of concurrent treatment, have been addressed elsewhere [5,9]. These 
problems are partially a consequence of the retrospective nature of many of the studies. 
A number of smaller investigations have reported chemotherapy of brain metastases to be ef- 
ficacious, particularly in previously untreated patients [9]. In studies using conventional combi- 
nation chemotherapy, brain metastases have responded at rates comparable to that found in 
other metastatic sites. Thus, the conception of the brain as a sanctuary is under reevaluation. 
Some of these trials have used chemotherapy alone in untreated patients. High-dose chemother- 
apy to patients relapsing with brain metastases has yielded some responses but at a cost of con- 
siderable toxicity 193. In view of the expected short survival of such patients it is currently ques- 
tionable if a possible therapeutic gain matches the adverse effects of such high-dose treatments. 
Randomized trials evaluating the need for combined chemo and radiotherapy in patients 
with newly diagnosed disease and brain metastases are needed. In addition, much information is 
needed on factors relevant to the evaluation of treatment outcome following radio- or che- 
motherapy. (1) What is the best measure of treatment effect? (2) What were the patients’ char- 
acteristics of those receiving compared with those not receiving CNS treatment? (3) What is the 
diagnostic and therapeutic delay? (4) How many patients with brain metastases did not receive 
treatment? (5) How many of the patients were newly diagnosed patients with SCLC. (6) How 
many patients had disease progression outside the CNS? (7) At what time after the last che- 
motherapy were the brain metastases diagnosed? (8) Do corticosteroids iniluence the effect of 
chemotherapy through its influence on brain capillary permeability? Prospective studies on both 
chemo- and radiotherapy accounting for these aspects are needed. Follow-up should be made 
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both with contrast enhanced CT-scan and evaluation of neurological function. 
Treatment of leptomeningeal carcinomatosis is still disappointing. This may partially be due 
to the frequent occurrence of multiple metastases when leptomeningeal carcinomatosis is found. 
This factor along with the lack of reliable objective parameters to monitor treatment outcome 
makes the interpretation of various treatment approaches difficult. Intrathecal chemotherapy 
with methotmxate remains the most widely used treatment [9]. Only limited information is 
available on the intrathecal use of other cytostatic agents. Alternatively, high-dose systemic eto- 
poside has been used with modest effect but again with considerable toxicity. Radiotherapy for 
bulky disease can be used, but irradiation to the whole neuraxis is only rarely indicated because 
of the risk of compromising the bone marrow capacity to withstand chemotherapy. 
There were no new data on treatment of spinal cord compression available for discussion. 
Sequelae to CNS treatment 
Since the 1981 workshop a number of retrospective analyses on neuropsychologic complica- 
tions in long-term survivors have appeared [83. They lack pretherapeutic evaluation and often 
consist of patients who have received slightly different treatments. These reports have raised 
concern for possible adverse effects in patients surviving for longer periods following F’CI. The 
contribution of different chemotherapeutic agents and the simultaneous administration of 
chemo- and radiotherapy is unclear. Aspects of these sequelae have been reviewed elsewhere in 
this issue [8]. Information on the quality of life in general and of the neuropsychological func- 
tion in particular is needed in prospective studies. Furthermore an evaluation of PC1 should also 
include contrast enhanced CT-scanning and nuclear magnetic resonance -)-imaging to see 
if additional information on CNS toxicity can be obtained by these diagnostic methods. 
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